NexgenRxNEGXF 40 EBIT per Share is $0.02 as of Mar. 2026. GuruFocus rates NEGXF with a GF Score™ of 40/100 and a GF Value™ of $0.27 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 527 Healthcare Providers & Services companies, NexgenRx ranks better than 96.96% on this metric.
NexgenRx's EBIT per Share for the
three
months ended in Mar. 2026 was $0.01.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $0.02.
During the past 12 months, the average EBIT per Share Growth Rate of NexgenRx was 137.50% per year.
During the past 3 years, the average EBIT per Share Growth Rate was 93.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for NexgenRx's EBIT per Share or its related term are showing as below:
NEGXF'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -51.9 Med: 20.2 Max: 93.5
Current: 93.5
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of NexgenRx was 93.50% per year. The lowest was -51.90% per year. And the median was 20.20% per year.
NEGXF's 3-Year EBIT Growth Rate is ranked better than 96.96% of 527
companies
in the Healthcare Providers & Services industry
Industry Median: 12.1
vs NEGXF: 93.50
NexgenRx's EBIT for the
three
months ended in Mar. 2026 was $0.88 Mil.
NexgenRx (OTCPK:NEGXF) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
NexgenRx EBIT per Share Related Terms
NexgenRx EBIT per Share Historical Data
* Premium members only.
The historical data trend for NexgenRx's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.02
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NexgenRx (NEGXF) has a EBIT per Share of $0.02 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on NexgenRx and its competitors. According to the industry distribution chart, NexgenRx ranks #16 out of 527 companies in the Healthcare Providers & Services industry, placing it in the top 3%.
Is NexgenRx's EBIT per Share too high?
NexgenRx's current EBIT per Share is $0.02. The Healthcare Providers & Services industry median EBIT per Share is 12.10. NexgenRx's value of $0.02 is 99.8% below this industry median. Based on the distribution chart, NexgenRx ranks #16 out of 527 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, NexgenRx has a GF Score™ of 40/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does NexgenRx's EBIT per Share compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, NexgenRx ranks #16 out of 527 companies for EBIT per Share. This places NexgenRx in the top 3% of its industry — outperforming the majority of peers. The industry median EBIT per Share is 12.10. NexgenRx's value of $0.02 is 99.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Healthcare Providers & Services company?
The median EBIT per Share among Healthcare Providers & Services companies is 12.10, based on 527 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NexgenRx's current EBIT per Share of $0.02 is 99.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on NexgenRx and its competitors. For the Healthcare Providers & Services industry, the median EBIT per Share is 12.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NexgenRx's current EBIT per Share is $0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NexgenRx stock overvalued right now?
Based on GuruFocus' analysis, NexgenRx (NEGXF) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.27, compared to a current price of $0.33 — trading 20.4% above its estimated fair value. The current EBIT per Share is $0.02 and 99.8% below the Healthcare Providers & Services industry median of 12.10. NexgenRx's overall GF Score™ is 40/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For NexgenRx (NEGXF), the current EBIT per Share is $0.02 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NexgenRx (NEGXF) Overvalued in 2026?
Based on GuruFocus' analysis, NexgenRx stock appears to be overvalued.
The current stock price of $0.33 is trading 20.4% above its estimated GF Value™ of $0.27.
GuruFocus considers NexgenRx to be Modestly Overvalued.
Key valuation signals for NEGXF:
EBIT per Share: $0.02
GF Value™: $0.27 vs. price of $0.33 (20.4% above fair value)
Industry Position: 99.8% below the Healthcare Providers & Services median (#16 of 527)
No single metric tells the full story. See the NEGXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NexgenRx Inc administers, adjudicates, and pays drug, dental and other extended health-care claims for the beneficiaries of health benefit plans underwritten by its customers using proprietary computer software and also provides ancillary services. The various solutions offered by the company include: NexSys, a fully integrated rules-based adjudication platform for real-time processing of drug, dental, and extended health benefit claims; NexAdmin, which enables sponsors to take complete control of benefit plan administration; and NexPSPAssist, a service that helps Patient Support Programs (PSP) to optimize their deliverables to their manufacturer clients. The company has only one operating segment - benefits administration services.
40GF Score
Get the complete analysis for NEGXF
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NEGXF has been successfully added to your 
